SCORE2 报告 24:视网膜中央静脉及半视网膜静脉阻塞中视网膜厚度与视力的非线性关系
SCORE2 研究对 64 个中心、接受阿柏西普或贝伐珠单抗治疗的视网膜中央静脉阻塞(CRVO)或半视网膜静脉阻塞(HRVO)继发黄斑水肿患眼随访至 60 个月,比较两段线性回归与简单线性回归模型。结果显示黄斑中心亚区厚度(CST)与视力字母评分(VALS)呈非线性关系,拐点估计为 217 至 256 μm,拐点左侧呈强正相关、右侧呈强负相关,所有基线后月份两段模型均优于一段模型(P < 0.001)。
要点
- CST 与 VALS 的关系呈非线性,拐点估计范围为 217 至 256 μm。
- 拐点左侧 CST 与 VALS 强正相关(r 0.29 至 0.50),右侧强负相关(r -0.43 至 -0.74)。
- 所有基线后月份两段模型均优于一段模型(P < 0.001)。
核心结论
- CRVO 或 HRVO 患眼接受抗血管内皮生长因子(VEGF)治疗后,CST 与 VALS 的关系并非简单线性。
- 治疗后 CST 接近估计拐点(217 至 256 μm)的 SCORE2 参与者表现出最佳 VALS。
- 在接受抗 VEGF 治疗 CRVO 或 HRVO 继发黄斑水肿的患者中,视网膜更薄并不总是与更好的 VALS 相关。
研究设计与样本
- 研究为在美国 64 个中心开展的随机临床试验后的长期随访。
- 参与者随访至 60 个月,完成 12 个月治疗方案后由研究者酌情治疗。
- 比较两段线性回归模型与 VALS 对 CST 的简单线性回归模型,并计算 Pearson 相关系数。
主要发现
- 在 7 个基线后访视计算的拐点范围为 217 至 256 μm。
- 每个估计拐点左侧呈强正相关,范围从 0.29(第 60 个月,P < 0.01)至 0.50(第 12 个月,P < 0.01)。
- 每个估计拐点右侧呈强负相关,范围从 -0.43(第 1 个月,P < 0.01)至 -0.74(第 24 个月,P < 0.01)。
- 随机化统计检验显示,所有基线后月份两段模型均优于一段模型(所有检验 P < 0.001)。
关键数值与推荐
- CST 由 OCT 测量,VALS 采用电子早期治疗糖尿病视网膜病变研究(ETDRS)方法测量。
- 拐点估计范围为 217 至 256 μm。
- 拐点左侧相关系数 0.29 至 0.50(P < 0.01),右侧相关系数 -0.43 至 -0.74(P < 0.01)。
- 两段模型优于一段模型的检验 P < 0.001。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To investigate whether a nonlinear association between central subfield thickness (CST) on spectral-domain OCT and concurrent visual acuity letter score (VALS) exists in eyes treated initially with aflibercept or bevacizumab for macular edema associated with central retinal vein occlusion (CRVO) or hemiretinal vein occlusion (HRVO) in the Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2). DESIGN: Long-term follow-up after a randomized clinical trial from 64 centers in the United States. PARTICIPANTS: Participants were followed up to 60 months and treated at investigator discretion after completing the 12-month treatment protocol. METHODS: Two-segment linear regression models were compared with simple linear regression models of VALS on CST. Pearson correlation coefficients were calculated to assess strength of CST and VALS associations. MAIN OUTCOME MEASURES: Central subfield thickness was measured by OCT and VALS by the electronic Early Treatment Diabetic Retinopathy Study methodology. RESULTS: Estimated inflection points, reflecting turning points at which the CST and VALS association changes from positive to negative, calculated at 7 postbaseline visits, range from 217 to 256 μm. A strongly positive correlation exists to the left of each estimated inflection point, ranging from 0.29 (P < 0.01 at month 60) to 0.50 (P < 0.01 at month 12), and a strongly negative correlation exists to the right of each estimated inflection point, ranging from -0.43 (P < 0.01 at month 1) to -0.74 (P < 0.01 at month 24). Randomization statistical tests showed that 2-segment models are favored over 1-segment models for all postbaseline months (P < 0.001 for all tests performed). CONCLUSIONS: The relationship between CST and VALS in eyes with CRVO or HRVO after treatment with anti-vascular endothelial growth factor (VEGF) therapy is not simply linear. The usually modest correlations between OCT-measured CST and visual acuity belie strong left and right correlations present in 2-segment models. Post-treatment CST close to the estimated inflection points showed the best expected VALS. The SCORE2 participants with a post-treatment CST after treatment close to the estimated inflection points of 217 to 256 μm showed the best VALS. In patients treated with anti-VEGF for macular edema associated with CRVO or HRVO, a thinner retina is not always associated with better VALS. FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.
引用
- Scott IU, Oden NL, VanVeldhuisen PC, et al. SCORE2 Report 24: Nonlinear Relationship of Retinal Thickness and Visual Acuity in Central Retinal and Hemiretinal Vein Occlusion. Ophthalmology. 2023. PMID: 37220815. doi:10.1016/j.ophtha.2023.05.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。